Afficher la notice abrégée

dc.creatorNtelis K., Solomou E.E., Sakkas L., Liossis S.-N., Daoussis D.en
dc.date.accessioned2023-01-31T09:40:51Z
dc.date.available2023-01-31T09:40:51Z
dc.date.issued2017
dc.identifier10.1016/j.semarthrit.2017.05.004
dc.identifier.issn00490172
dc.identifier.urihttp://hdl.handle.net/11615/77338
dc.description.abstractIntroduction Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, autoimmunity, and widespread dermal and visceral fibrosis. This article summarizes the current knowledge about the potential contribution of platelets in the disease process and the rationale of targeting platelets as an adjunct treatment for SSc. Methods We performed an electronic search (Medline) using the keywords platelets, systemic sclerosis, autoimmunity, fibrosis, Raynaud, and pulmonary arterial hypertension. Results The link that connects vasculopathy, autoimmunity, and fibrosis in SSc remains obscure. Experimental data suggest that platelets are not solely cell fragments regulating hemostasis but they have a pleiotropic role in several biologic processes including immune regulation, vasculopathy, fibrosis, and all key features of SSc. Platelets interplay with the impaired endothelium, can interact with immune cells, and they are storages of bioactive molecules involved in tissue injury and remodeling. The potential role of platelets in the pathogenesis of SSc is further supported by experimental data in animal models of SSc. Platelet-derived serotonin represents a novel target in SSc and serotonin blockade is currently being tested in clinical trials. Conclusion Platelets may be actively involved in the pathogenesis of SSc by activating immune responses and facilitating the fibrotic process. However, definite conclusions cannot be drawn until more data from both basic and clinical research are available. © 2017 Elsevier Inc.en
dc.language.isoenen
dc.sourceSeminars in Arthritis and Rheumatismen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85020306401&doi=10.1016%2fj.semarthrit.2017.05.004&partnerID=40&md5=f44d9b5347bad66690a144f14ec4db3d
dc.subjectserotoninen
dc.subjectautoantibodyen
dc.subjectserotoninen
dc.subjectautoimmunityen
dc.subjectcell interactionen
dc.subjectdisease courseen
dc.subjectendothelial dysfunctionen
dc.subjectendothelium injuryen
dc.subjectfibrosisen
dc.subjecthumanen
dc.subjectimmune responseen
dc.subjectimmunocompetent cellen
dc.subjectimmunological toleranceen
dc.subjectimmunopathogenesisen
dc.subjectimmunoregulationen
dc.subjectinflammationen
dc.subjectmicroangiopathyen
dc.subjectnonhumanen
dc.subjectplatelet microparticleen
dc.subjectpleiotropyen
dc.subjectpriority journalen
dc.subjectpulmonary hypertensionen
dc.subjectRaynaud phenomenonen
dc.subjectReviewen
dc.subjectserotonin releaseen
dc.subjectsystemic sclerosisen
dc.subjectthrombocyteen
dc.subjectthrombocyte activationen
dc.subjectthrombocyte aggregationen
dc.subjectthrombosisen
dc.subjecttissue injuryen
dc.subjecttissue regenerationen
dc.subjectvascular diseaseen
dc.subjectvascular endotheliumen
dc.subjectvascular remodelingen
dc.subjectanimalen
dc.subjectB lymphocyteen
dc.subjectblooden
dc.subjectcomplicationen
dc.subjectfibrosisen
dc.subjectimmunologyen
dc.subjectmetabolismen
dc.subjectpathologyen
dc.subjectsystemic sclerosisen
dc.subjectthrombocyteen
dc.subjectAnimalsen
dc.subjectAutoantibodiesen
dc.subjectAutoimmunityen
dc.subjectB-Lymphocytesen
dc.subjectBlood Plateletsen
dc.subjectFibrosisen
dc.subjectHumansen
dc.subjectHypertension, Pulmonaryen
dc.subjectRaynaud Diseaseen
dc.subjectScleroderma, Systemicen
dc.subjectSerotoninen
dc.subjectW.B. Saundersen
dc.titleThe role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosisen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée